Last Updated on November 12, 2021 by The Health Master
NEW YORK: The Oklahoma State Supreme Court on Tuesday, November 9, 2021, overturned a historic decision to fine US pharmaceutical giant Johnson & Johnson $465 million for its role in the opioid crisis.
In 2019, a judge ordered the company to pay the sum to finance programs to combat the opioid crisis, which has caused more than 500,000 deaths in 20 years in the United States.
The judge ruled the company had created a “public nuisance” with its marketing of prescription pain pills, saying it had adopted “deceptive” marketing practices to promote opioids.
It was the first civil judgment linked to opiates against a drug company in the United States. The state initially claimed some $17 billion dollars in costs, corresponding to 20 years of financing of these programs.
On appeal, the Oklahoma Supreme Court ruled the judge should not have relied on the public nuisance law to condemn J&J’s manufacturing, marketing and sales practices, and overturned his decision.
Johnson & Johnson , like other pharmaceutical giants such as Purdue, the manufacturer of OxyContin, and major US drug distributors, have been accused of over-promoting their pain-relieving drugs from 1996 onwards, causing a crisis in addiction and an explosion of overdoses.
Distributors AmerisourceBergen, Cardinal Health and McKesson, as well as J&J, agreed in late July to pay $26 billion to settle thousands of disputes related to the opioid crisis.
Johnson & Johnson said in June that it had stopped production and sale of prescription opioid medications in the United States.
For its part, Purdue, for its part, declared bankruptcy and agreed to pay $4.5 billion to victims and institutions that had been affected, in exchange for a certain civil immunity for its owners, the Sackler family. That case is still ongoing.
Molecular testing in guiding Blood Cancer treatment
No allopathic drug found in Jackfuit365 flour: Lab test
USFDA gives final nod to Zydus Cadila for Glycopyrrolate Injection
Oral and Nasal Vaccines for Covid are on horizon: WHO
CDSCO extends the timeline for licensing of these Medical Devices
Govt agrees with proposal to grant Jan Aushadhi license only to Registered Pharmacists
Kerala to prepare Pharmacy Graduates for multiple opportunities in Govt sector
Para 19 of DPCO: IDMA urges Govt to allow Pharma industry to hike Drugs prices
Latest on National Formulary of India (NFI)
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
